FierceBiotech Special Report: China’s Rise Drives Investment in Biotech Drugs

Leave a comment

Until recently, the history of the pharmaceutical industry in China was more about imitation than innovation.

According to a report by London-based market researcher Scrip Intelligence, approximately 40% of biotech sales in China come from biosimilars. This would explain why the market for biologics in China has been growing at a rate of more than 25% a year, while total sales of biotech drugs are still only $1.5 billion a year.  Read more

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s